Nucleai, Gilead Collaborate on Tissue Analysis in Cancer Therapy Development
Nucleai is analyzing whole-slide images across multiple oncology studies to support Gilead's antibody-drug conjugate programs.
Ion Genomics
Ion Genomics is a podcast and newsletter featuring news and analysis of sequencing, cancer testing, AI virtual cells, and more of the hottest topics in biology and precision medicine.
Subscribe:.rss.atom.json.md.m3u.pls
Live Last read · last published · next check
Latest episodes
Saves to your Listen queue, to pick up on another day or another device.
Technology, Trust, and Tuberculosis, with Journalist Will Herkewitz
A dispatch from the front lines of the new Ebola epidemic in the DRC and the fight against tuberculosis in the US.
FDA Grants Breakthrough Device Designation to Freenome's SimpleScreen Lung Test
The designation could speed FDA review of SimpleScreen Lung for high-risk adults not currently screened for lung cancer.
Natera, Germany’s Kupando Partner to Track ctDNA Dynamics in Phase 1 Skin Cancer Trial
The test will monitor circulating tumor DNA dynamics in Kupando Therapeutics' Phase 1 trial of KUP-101 in patients with advanced skin cancers.
PacBio CEO Change Fallout: Newsletter Aug. 11, 2026
Illumina settles with Carl Icahn, 10x Genomics gets sued, WuXi AppTec exposes DoD incompetence, inside a MinIon flow cell, Natera Q2 bonanza, and more.
New PacBio CEO Has Been Preparing for His Moment
Like a Hemingway bankruptcy, Mark Van Oene’s rise to the top job at PacBio was gradual and then sudden.
Illumina Settles Icahn-Led Shareholder Suit Over Grail Saga
The no-payment settlement resolves one of several lingering shareholder suits over Illumina's contested Grail reacquisition.
Raw Reads: AI Trends with 10x Genomics CEO Serge Saxonov
10x Genomics CEO Serge Saxonov mentioned AI's impact on his company many times during a conference call with Wall Street analysts.
Natera Q2 Revenue Jumps 38 Percent, Company Raises Full-Year Outlook by $100 Million
The cell-free DNA testing company processed approximately 283,000 Signatera tests en route to revenue of $752.8 million.
10x Genomics Q2 Revenue Falls 13 Percent on Decline in Patent Suit Windfalls
The single-cell and spatial biology company reported Q2 revenue of $151.0 million, with a sharp decline in instrument revenue as customers await Atera.